Field Medical Request for an Off-Label Combination IIT

Separate the two interactions. The dinner question is an unsolicited clinical inquiry; the IIT request is a formal research funding request. Priya should not answer the hepatic-impairment dosing question with a personal recommendation. She can say the approved label specifies a dose reduction for moderate hepatic impairment and offer the label plus the medical information response; she should not extrapolate that to the first-line combination. For the combination question, she can discuss only published data and must state that no first-line combination data exist. She should not endorse the regimen or say it is 'reasonable.' On the IIT: thank Dr. Marsh, explain the biannual committee and three-week deadline, direct her to the portal, and make no funding commitment. Even if the manager says it is likely fundable, Priya cannot promise support. Document both interactions in the CRM, including the off-label question and her response. If Dr. Marsh asks for the conversation to stay informal, Priya should explain that all requests are handled consistently. This protects the relationship without creating promotional or contractual risk.

Before review, Priya should confirm the proposal is submitted through the IIT portal with a protocol, budget, site CV, IRB plan, and data/publication rights. She should verify the practice can recruit 40 first-line patients and that the fellow has supervision. She must check for conflicts: Dr. Marsh's consulting or speaking roles, the fellow's employment, and any company commercial involvement. The budget should be fair market value and not tied to prescribing. The contract must preserve investigator independence, company access to data, and publication rights without company approval of conclusions. Documentation: CRM entry, email trail, committee submission date, and a note that no support was promised. The manager's 'keep warm' instruction should be escalated if it becomes pressure to prejudge. Medical affairs may provide drug supply or assay support only through policy. The key reasoning is that IIT support is a scientific review, not a sales tool; prior commitment would undermine fair review and could look like an inducement.

If the committee declines, Priya should communicate promptly in writing, with the scientific rationale: for example, single-center retrospective design, small sample, off-label first-line combination, lack of preliminary data, or budget prioritization. She should avoid implying the decision is about the relationship or the fellow's quality. She can offer alternatives within policy: medical information, published literature, investigator training, a letter of support without funding, or resubmission after generating pilot data. She must not offer a different funding route through commercial. She should continue responding to unsolicited scientific questions and document the conversation. If Dr. Marsh is upset, Priya should acknowledge disappointment, restate the process, and offer a debrief with the committee chair if permitted. This preserves trust because the decision is transparent, consistent, and separated from promotional interests.